Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 1.00 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 1.00 |
| ▸ | METTL3 | Q86U44 | 8/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Onametostat SCHEMBL29394859 | 1.00 | PRMT5 (1.00) | PRMT5WDR77METTL3 | |
| Onametostat SCHEMBL18572106 | 1.00 | PRMT5 (1.00) | PRMT5WDR77METTL3 | |
| Onametostat SCHEMBL29352669 | 1.00 | PRMT5 (1.00) | PRMT5WDR77METTL3 | |
| Onametostat SCHEMBL29485640 | 1.00 | PRMT5 (1.00) | PRMT5WDR77METTL3 | |
| Onametostat SCHEMBL25427100 | 1.00 | PRMT5 (1.00) | PRMT5WDR77METTL3 | |
| Onametostat SCHEMBL25318935 | 1.00 | PRMT5 (1.00) | PRMT5WDR77METTL3 | |
| Onametostat SCHEMBL22749057 | 1.00 | PRMT5 (1.00) | PRMT5WDR77METTL3 | |
| Onametostat SCHEMBL22468844 | 1.00 | PRMT5 (1.00) | PRMT5WDR77METTL3 | |
| Onametostat SCHEMBL22749068 | 1.00 | PRMT5 (1.00) | PRMT5WDR77METTL3 | |
| Onametostat SCHEMBL27430557 | 1.00 | PRMT5 (1.00) | PRMT5WDR77METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707931-A | Intermediate and synthesis method of 1- (1-oxo-1, 2-dihydro-phthalazin-6-yl) cycloalkyl-1-carboxamide derivatives as MTA synergistic inhibitors of PRMT5 | 百济神州(北京)生物科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-118891379-A | Cancer diagnosis and treatment by PRMT5 inhibitors | 阿古诺治疗有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-118846060-A | Application of METTL inhibitor in preparation of medicine for treating drug-induced liver injury | 中山大学附属第三医院 | 2024-10-29 | — | — | CN | disclosed |
| CN-118871432-A | 4- (Aminomethyl) -6- (1-methyl-1H-pyrazol-4-yl) isoquinolin-1 (2H) -one derivatives as MTA synergistic inhibitors of PRMT5 | 百济神州有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20230241087-A1 | Methods Of Treating Cancer Using Prmt5 Inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-03 | — | — | US | disclosed |
| US-11571437-B2 | Methods of treating cancer using PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-07 | — | — | US | disclosed |
| EP-3980019-A1 | METHODS OF TREATING CANCER USING PRMT5 INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2022-04-13 | — | — | EP | disclosed |
| CN-113966232-A | Methods of treating cancer using PRMT5 inhibitors | 詹森药业有限公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11571437-B2 | Methods of treating cancer using PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 118/4885METTL3 80/4885 |
| US-20230241087-A1 | Methods Of Treating Cancer Using Prmt5 Inhibitors | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 223/4885METTL3 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.